Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Attack dataset continues to accumulate in RAPIDe-3, a pivotal ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

A new medication called lorundrostat has shown strong potential as a treatment for people with uncontrolled or resistant high ...

A pending Department of Health and Human Services regulation risks harming public health and stalling innovation.

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The treatment could also delay the need for gruelling chemotherapy, according to the trial. | ITV National News ...

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

Different dosages of brensocatib proved effective in treating people living with bronchiectasis when studied in the ASPEN ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests - ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...